AZ-23 is a potent, selective, orally bioavailable Trk kinase inhibitor with IC50 of 2 and 8 nM for TrkA and TrkB, respectively.
AZ-23 displays >10-fold specificity for TrkA versus FGFR1 and >25-fold over a broad panel of kinases.
AZ-23 potently inhibits NGF-induced TrkA/B/C phosphorylation in NIH-3T3 cells with IC50 of 2 nM, 25-fold window of selectivity versus FGFR, Flt3, Ret, and Lck kinases.
AZ-23 exhibits significant tumor growth inhibition in Trk-expressing xenograft model of neuroblastoma.
